
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Approvals· August 29, 2026 · 15 min read
By Ran Chen#FDA Approval#JAK Inhibitor#Dermatology

Approvals· August 29, 2026 · 24 min read
Mimrylo for PV Erythrocytosis: 76.9% Week 20-32 Response and Platelet Rises
By Ran Chen#FDA Approval#Hematology#Coverage Access

Approvals· August 29, 2026 · 17 min read
Rasonque's Pancreatic Label Needs No RAS Test: 2L Data Does Not Write 1L Access
By Ran Chen#FDA Approval#Oncology#Coverage Access

Approvals· August 27, 2026 · 20 min read
Imaavy's wAIHA Approval Is a Steroid-Gated, q4w Indication: J9256 Does Not Auto-Cover It

Approvals· August 27, 2026 · 18 min read
Tivicay PD's Neonatal Expansion: Term, 2 kg Floor; Tablets Do Not Substitute
By Ran Chen#FDA Approval#HIV#Infectious Disease

Policy· August 24, 2026 · 18 min read
FDA's Expedited IND Pilot: 30-Day Safe-to-Proceed Clock and QRI Review
By Ran Chen#FDA Approval#Clinical Evidence#Pipeline

Approvals· August 23, 2026 · 18 min read
Besremi's August 30 ET PDUFA: Second-Line vs Anagrelide, Not Hydroxyurea
By Ran Chen#PDUFA Date#FDA Approval#Orange Book

Generics· August 23, 2026 · 17 min read
FDA's August 2026 TE Final: 505(b)(2) Requests and Orange Book Blanks
By Ran Chen#Orange Book#505(b)(2)#FDA Approval

Approvals· August 22, 2026 · 19 min read
Zilganersen's September 22 PDUFA: Alexander Disease ASO & Intrathecal Access
By Ran Chen#FDA Approval#NDA Approval#Priority Review

Generics· August 21, 2026 · 17 min read
The Estradiol Patch Shortage: Reading FDA's Database Against ASHP Bulletins
By Ran Chen#Supply Chain#Generics#Orange Book